PARADIGM BIOPHARMACEUTICALS
Who is PARADIGM BIOPHARMACEUTICALS?
Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regenerati...See more
Industry & Specialities
Pharmaceuticals
Manufacturing
Countries of Operation
Australia
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
11-50 Employees
Year Founded:
2014 (12 years)
Address:
500 COLLINS; L2 517 FLINDERS LANE; MELBOURNE, VICTORIA 3000, AU
Employees by Department
- Operations (2)
- Sales (2)
- IT / Product (1)
- The Rest (7)
- Total (12)
Key Decision Makers
Paul Rennie
CEO
Beverley Huttmann
Head of Business Development
Sarah Kelly
Clinical Operations Lead
Rachel Peat
Medical Affairs Manager
Employees by Seniority
C-level
1employees
Senior
1employees
Non-managers
1employees
Financials
LOW
spending power
Funding Status
Publicly listed on stock exchange
Associated Legal Entities
0 entities
Discover More Companies
Lookalike companies
Featured Lists
- SMEs in Singapore
- MNCs / Large Enterprises in Singapore
Frequently Asked Questions (FAQ)
- How long has PARADIGM BIOPHARMACEUTICALS been operating for?
- What is the funding status of PARADIGM BIOPHARMACEUTICALS?
- Where is PARADIGM BIOPHARMACEUTICALS's headquarter?
- What PARADIGM BIOPHARMACEUTICALS's spending power?
- Does PARADIGM BIOPHARMACEUTICALS have a presence in the domain it operates in?